Controlled Substances Act

The Controlled Substances Act (CSA) is the primary federal drug policy statute in the United States, establishing a comprehensive legal framework for the manufacture, importation, possession, use, and distribution of certain substances.

Legislative History and Purpose

Enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, the CSA was signed into law by President Richard Nixon. It replaced and consolidated numerous previous laws governing narcotics and other drugs. The primary purposes of the Act are to combat drug abuse, control the trafficking of addictive or dangerous substances, and conform to international treaty obligations, such as the Single Convention on Narcotic Drugs (1961). The CSA aims to provide a "closed" system of distribution for controlled substances, tracking them from manufacture or import to final dispensation.

Scheduling System and Criteria

A cornerstone of the CSA is its five-tiered scheduling (classification) system, which places drugs into one of five schedules (I-V) based on their potential for abuse, accepted medical use in the United States, and safety or dependence liability under medical supervision.

• Schedule I: Substances with a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Examples include heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), and 3,4-methylenedioxymethamphetamine (MDMA or ecstasy).
• Schedule II: Substances with a high potential for abuse, a currently accepted medical use (or use with severe restrictions), and abuse of which may lead to severe psychological or physical dependence. Examples include cocaine, methamphetamine, most pure opioid agonists (e.g., fentanyl, oxycodone, morphine), and certain short-acting barbiturates.
• Schedule III: Substances with a moderate to low potential for physical and high psychological dependence, a currently accepted medical use, and abuse potential less than Schedules I and II. Examples include anabolic steroids, ketamine, and products containing less than 90 milligrams of codeine per dosage unit.
• Schedule IV: Substances with a low potential for abuse relative to Schedule III, a currently accepted medical use, and limited dependence liability. Examples include benzodiazepines (e.g., diazepam, alprazolam), some sleep medications (e.g., zolpidem), and certain long-acting barbiturates.
• Schedule V: Substances with a lower potential for abuse than Schedule IV, consisting primarily of preparations containing limited quantities of certain narcotics, generally for antitussive or antidiarrheal purposes. Examples include cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.

The authority to add, remove, or reschedule substances rests with the Attorney General, though in practice it is delegated to the Drug Enforcement Administration (DEA). The process involves scientific and medical evaluations from the Department of Health and Human Services (HHS).

Regulatory Provisions and Enforcement

The CSA establishes strict registration, record-keeping, and security requirements for all entities involved in the legitimate supply chain of controlled substances, including manufacturers, distributors, pharmacies, hospitals, and practitioners (doctors, dentists, veterinarians). Practitioners must register with the DEA to prescribe, administer, or dispense controlled substances. The Act also sets production quotas for Schedule I and II substances to prevent diversion. Enforcement is carried out primarily by the DEA, with violations carrying significant criminal and civil penalties. Penalties vary based on the schedule of the substance, the amount involved, and the type of violation (e.g., trafficking vs. simple possession).

Impact and Controversies

The CSA has profoundly shaped U.S. drug policy, criminal justice, and medical practice for over five decades. It has been central to the "War on Drugs," contributing to high rates of incarceration for drug offenses. Major controversies persist, particularly around the scheduling of certain substances. Critics argue that the placement of marijuana in Schedule I, despite growing evidence of medical utility and its legalization for medical or recreational use in many states, creates a conflict between federal and state law and hinders research. The opioid crisis has also brought scrutiny to the Act's role in regulating pharmaceutical opioids, with debates over balancing access for legitimate pain management against the risk of diversion and abuse. Furthermore, the scheduling of certain psychedelics (e.g., psilocybin, MDMA) is contested by researchers exploring their therapeutic potential for conditions like depression and PTSD.